Arrowhead amends bylaws to add proxy access, update stockholder nomination rules

ARROWHEAD PHARMACEUTICALS, INC.

Board adopted Second Amended and Restated Bylaws effective January 24, 2023.
Adds proxy access: stockholder or group of up to 20 owning 3% for 3 years may nominate up to 20% of board or two directors.
Updates procedural mechanics for stockholder nominations and business proposals.
Requires a proxy card color other than white for stockholders soliciting proxies from others.
Conforms bylaws to recent Delaware General Corporation Law amendments.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

ARROWHEAD PHARMACEUTICALS, INC.: Amended and restated bylaws with updates including proxy access provisions, procedural mechanics, and conforming changes (effective 2023-01-24).

Change: bylaw amendment
Effective: 2023-01-24

Exact text from the filing

On January 24, 2023, the Board of Directors (the “Board”) of Arrowhead Pharmaceuticals, Inc. (the “Company”) amended and restated the Company's Amended and Restated Bylaws (the “Second Amended and Restated Bylaws”), which became effective immediately.

View on SEC.gov

Browse all governance changes →

ARROWHEAD PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001628280-23-001757

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.